Astrocytes and Glutamate Homoeostasis in Alzheimer’s Disease: A Decrease in Glutamine Synthetase, But Not in Glutamate Transporter-1, in the Prefrontal Cortex
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Astrocytes control tissue equilibrium and hence define the homoeostasis and function of the CNS (central nervous system). Being principal homoeostatic cells, astroglia are fundamental for various forms of neuropathology, including AD (Alzheimer's disease). AD is a progressive neurodegenerative disorder characterized by the loss of cognitive functions due to specific lesions in mnesic-associated regions, including the mPFC (medial prefrontal cortex). Here, we analyzed the expression of GS (glutamine synthetase) and GLT-1 (glutamate transporter-1) in astrocytes in the mPFC during the progression of AD in a triple-transgenic mouse model (3xTg-AD). GS is an astrocyte-specific enzyme, responsible for the intracellular conversion of glutamate into glutamine, whereas the removal of glutamate from the extracellular space is accomplished mainly by astroglia-specific GLT-1. We found a significant decrease in the numerical density (Nv, cells/mm3) of GS-positive astrocytes from early to middle ages (1-9 months; at the age of 1 month by 17%, 6 months by 27% and 9 months by 27% when compared with control animals) in parallel with a reduced expression of GS (determined by Western blots), which started at the age of 6 months and was sustained up to 12 months of age. We did not, however, find any changes in the expression of GLT-1, which implies an intact glutamate uptake mechanism. Our results indicate that the decrease in GS expression may underlie a gradual decline in the vital astrocyte-dependent glutamate-glutamine conversion pathway, which in turn may compromise glutamate homoeostasis, leading towards failures in synaptic connectivity with deficient cognition and memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · cited 2×
“AD is a neurodegenerative disorder characterized by defined histopathological hallmarks [intracellular and extracellular aggregation of Aβ (β-amyloid) and intraneuronal accumulation of hyperphoshorylated Tau protein] and manifested by progressive memory loss and cognitive decline (Selkoe, 2001; Cummings, 2004; Battagl…”
BackgroundDanbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Control of Synapse Number by Glia
Ullian, E. M., Sapperstein, S. K., Christopherson, K. S., & Barres, B. A. (2001) · Science · doi:10.1126/science.291.5504.657 · Cited by 1,380
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296 · cited 2×
“, 1999), whereas reduced GS activity was found in hepatic encephalopathy, spinocerebellar atrophy, schizophrenia and epilepsy (Lavoie et al., 1987; Smith et al., 1991; Kish et al., 1994; Le Prince et al., 1995; Burbaeva et al., 2003; van der Hel et al., 2005; Steffek et al., 2008).”
BackgroundCummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 3×
“…(CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. previously and above in the introduction (Oddo et al., 2003a, 2003b; Rodriguez et al., 2008; Rodriguez et al., 2009a).”
BackgroundInfluentialGlutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease
HYND, M. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.007 · Cited by 938
Heidbreder, C. A., & Groenewegen, H. J. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.09.003 · Cited by 882 · cited 1×
“Those changes can account for the early as well as the late cognitive impairments in the mPFC region, including personality changes and memory formation (Heidbreder and Groenewegen, 2003).”
BackgroundLong-term potentiation and functional synapse induction in developing hippocampus
Durand, G. M., Kovalchuk, Y., & Konnerth, A. (1996) · Nature · doi:10.1038/381071a0 · Cited by 789 · cited 1×
“Glutamatergic signalling is responsible for synapse formation and elimination, as well as for the regulation of neural cell migration, differentiation, survival and death (Komuro and Rakic, 1993; Durand et al., 1996; Danbolt, 2001).”
BackgroundMicroglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease
Fuhrmann, M., Bittner, T., Jung, C. K. E., Burgold, S., Page, R. M., Mitteregger, G., Haass, C., LaFerla, F. M., Kretzschmar, H., & Herms, J. (2010) · Nature Neuroscience · doi:10.1038/nn.2511 · Cited by 562 · cited 1×
“3xTg-AD mice also show a certain level of neuronal loss accompanied by spine loss on dystrophic dendrites making the model relevant for studying alterations in synaptic transmission (Bittner et al., 2010; Fuhrmann et al., 2010).”
BackgroundOlabarria, M., Noristani, H. N., Verkhratsky, A., & Rodríguez, J. J. (2010) · Glia · doi:10.1002/glia.20967 · Cited by 499 · cited 2×
“Considering our previous results showing a decrease in the GFAPIR in astroglia in AD (Olabarria et al., 2010; Rodriguez and Verkhratsky, 2011; Kulijewicz-Nawrot et al., 2012) we may suggest that it is indeed the down-regulation of GFAP which may trigger/force the changes in GS distribution and expression level.”
ResultSelf-citationWilhelmsson, U., Li, L., Pekna, M., Berthold, C.-H., Blom, S., Eliasson, C., Renner, O., Bushong, E., Ellisman, M., Morgan, T. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0820-04.2004 · Cited by 455 · cited 2×
“The specificity of the antibody has been reported previously using immunohistochemistry and Western blotting (Pike et al., 1996; Wilhelmsson et al., 2004; Sen et al., 2011).”
MethodResultRodríguez, J. J., Jones, V. C., Tabuchi, M., Allan, S. M., Knight, E. M., LaFerla, F. M., Oddo, S., & Verkhratsky, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002935 · Cited by 377 · cited 3×
“…(CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. previously and above in the introduction (Oddo et al., 2003a, 2003b; Rodriguez et al., 2008; Rodriguez et al., 2009a).”
BackgroundMethodSelf-citationLI, S., MALLORY, M., ALFORD, M., TANAKA, S., & MASLIAH, E. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00008 · Cited by 343
A focus on the synapse for neuroprotection in Alzheimer disease and other dementias
Coleman, P., Federoff, H., & Kurlan, R. (2004) · Neurology · doi:10.1212/01.wnl.0000140626.48118.0a · Cited by 314 · cited 1×
“The fact that cognitive deficits are detected long before the clinical diagnosis of AD is made is becoming commonly accepted (Coleman et al., 2004).”
BackgroundGlial and glutamatergic markers in depression, alcoholism, and their comorbidity
Miguel-Hidalgo, J. J., Waltzer, R., Whittom, A. A., Austin, M. C., Rajkowska, G., & Stockmeier, C. A. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.003 · Cited by 218 · cited 5×
“As revealed by microarray and Western blot analyses, the expression of GS is significantly lower in depressed patients, further corroborating the fundamental importance of astrocytes to the disorder (Choudary et al., 2005; Miguel-Hidalgo et al., 2010).”
BackgroundInfluentialCortical Plasticity in Alzheimer’s Disease in Humans and Rodents
Battaglia, F., Wang, H.-Y., Ghilardi, M. F., Gashi, E., Quartarone, A., Friedman, E., & Nixon, R. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.027 · Cited by 175 · cited 3×
“AD is a neurodegenerative disorder characterized by defined histopathological hallmarks [intracellular and extracellular aggregation of Aβ (β-amyloid) and intraneuronal accumulation of hyperphoshorylated Tau protein] and manifested by progressive memory loss and cognitive decline (Selkoe, 2001; Cummings, 2004; Battagl…”
BackgroundGlutamate–glutamine cycling in Alzheimer's disease
WALTON, H., & DODD, P. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.10.007 · Cited by 174 · cited 6×
“Glutamate is the principal excitatory neurotransmitter in the CNS, and its metabolism depends on astrocytes (Fonnum, 1984; Anderson and Swanson, 2000; Walton and Dodd, 2007).”
BackgroundMethodInfluentialKulijewicz‐Nawrot, M., Verkhratsky, A., Chvátal, A., Syková, E., & Rodríguez, J. J. (2012) · Journal of Anatomy · doi:10.1111/j.1469-7580.2012.01536.x · Cited by 160 · cited 6×
“Immunohistochemistry The procedure for immunohistochemistry was the same as described previously [for details see (Olabarria et al., 2011; Yeh et al., 2011; Kulijewicz-Nawrot et al., 2012)].”
BackgroundMethodResultInfluentialMultiple events lead to dendritic spine loss in triple transgenic Alzheimer’s disease mice
Bittner, T., Fuhrmann, M., Burgold, S., Ochs, S. M., Hoffmann, N., Mitteregger, G., Kretzschmar, H., LaFerla, F. M., & Herms, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015477 · Cited by 149 · cited 1×
“3xTg-AD mice also show a certain level of neuronal loss accompanied by spine loss on dystrophic dendrites making the model relevant for studying alterations in synaptic transmission (Bittner et al., 2010; Fuhrmann et al., 2010).”
BackgroundDecreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1 H-MRS at 0.5 T
Antuono, P. G., Jones, J. L., Wang, Y., & Li, S.-J. (2001) · Neurology · doi:10.1212/wnl.56.6.737 · Cited by 119
Cited by
Manganese Is Essential for Neuronal Health
Horning, K. J., Caito, S. W., Tipps, K. G., Bowman, A. B., & Aschner, M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034419 · Cited by 602
Astrocytes in physiological aging and Alzheimer’s disease
Rodríguez-Arellano, J. J., Parpura, V., Zorec, R., & Verkhratsky, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.007 · Cited by 439
Self-citationGlutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration
Andersen, J. V., Markussen, K. H., Jakobsen, E., Schousboe, A., Waagepetersen, H. S., Rosenberg, P. A., & Aldana, B. I. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108719 · Cited by 371
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312
Deciphering the astrocyte reaction in Alzheimer's disease
Perez-Nievas, B. G., & Serrano-Pozo, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00114 · Cited by 282
“These thorn-shaped astrocytes have also been identified in the brain of individuals with AD (Lace et al., 2012; López-González et al., 2013; Figure 4E).”
Background
Metadata
- Authors
- Kulijewicz-Nawrot, M., Syková, E., Chvátal, A., Verkhratsky, A., & Rodríguez, J. J.
- Venue
- ASN Neuro
- Publisher
- Informa UK Limited
- Published
- 2013-08
- Volume
- 5
- Issue
- 4
- Pages
- 273-82
- ISSN
- 1759-0914 (ISSN-L)
- OpenAlex
- W2094805317
- Cited by
- 136
- References
- 22
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.